Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592353 | SCV000703048 | uncertain significance | not provided | 2016-10-31 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000592353 | SCV001145433 | uncertain significance | not provided | 2019-06-12 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000592353 | SCV002301936 | likely benign | not provided | 2022-11-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002532405 | SCV003615797 | uncertain significance | Inborn genetic diseases | 2024-11-13 | criteria provided, single submitter | clinical testing | The c.5593C>T (p.R1865W) alteration is located in exon 27 (coding exon 26) of the SPTBN2 gene. This alteration results from a C to T substitution at nucleotide position 5593, causing the arginine (R) at amino acid position 1865 to be replaced by a tryptophan (W). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000592353 | SCV005412380 | uncertain significance | not provided | 2024-05-15 | criteria provided, single submitter | clinical testing | PM2 |